Condition
Obese Subjects
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownThe Mediterranean Diet Based on Local Foods for Obese PatientsNCT07461870 · 2025-12-09
ACTIVE_NOT_RECRUITINGInnovative Functional Product for Overweight and ObesityNCT07044167 · 2025-09-07
COMPLETEDBrain Gym Exercises on Risk of Fall, Balance and Quality of Life in Obese SubjectsNCT06587932 · 2024-10-01
COMPLETEDConstruction of an in Vitro Intestinal Microbial Ecological Simulation System for Obese PeopleNCT06621186 · 2024-10-01
COMPLETEDA Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680 · 2023-04-06
COMPLETEDCommon interventions
atorvastatinDRUG1brain gym exercisesOTHER1Control without active polyphenolsDIETARY_SUPPLEMENT1digoxinDRUG1IBI362DRUG1Locally Adapted Mediterranean DietOTHER1Low calorie dietOTHER1metforminDRUG1No intervention measuresOTHER1Polyphenol-enriched functional productDIETARY_SUPPLEMENT1Traditional treatmentsOTHER1warfarinDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
COMPLETED4
ACTIVE_NOT_RECRUITING1
Phase mix
NA3
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.